
Sign up to save your podcasts
Or


In an industry known for pushing the bounds of human innovation, tech elites are now trying to push the bounds of their own bodies. The hot new biohacking trend is injectable peptides — similar to the ones found in GLP-1 medications like Ozempic. But these are not approved by the Food and Drug Administration.
These gray-market peptides, largely from Chinese manufacturers, are being used by tech workers and founders. Not just to lose weight, but to optimize their health and performance in all manner of ways. “Marketplace Tech” host Meghan McCarty Carino speaks with independent journalist Jasmine Sun, who recently wrote about this for the New York Times.
By Marketplace4.5
12541,254 ratings
In an industry known for pushing the bounds of human innovation, tech elites are now trying to push the bounds of their own bodies. The hot new biohacking trend is injectable peptides — similar to the ones found in GLP-1 medications like Ozempic. But these are not approved by the Food and Drug Administration.
These gray-market peptides, largely from Chinese manufacturers, are being used by tech workers and founders. Not just to lose weight, but to optimize their health and performance in all manner of ways. “Marketplace Tech” host Meghan McCarty Carino speaks with independent journalist Jasmine Sun, who recently wrote about this for the New York Times.

30,816 Listeners

25,970 Listeners

8,797 Listeners

14,615 Listeners

933 Listeners

1,390 Listeners

2,176 Listeners

5,492 Listeners

57,062 Listeners

9,585 Listeners

10,318 Listeners

5,477 Listeners

3,615 Listeners

6,447 Listeners

6,469 Listeners

163 Listeners

2,992 Listeners

1,375 Listeners

426 Listeners

92 Listeners

422 Listeners